AngioDynamics, Inc. (NASDAQ:ANGO - Get Free Report) SVP Warren Nighan, Jr. sold 23,370 shares of the firm's stock in a transaction on Thursday, July 30th. The shares were sold at an average price of $14.72, for a total value of $344,006.40. Following the sale, the senior vice president directly owned 64,745 shares of the company's stock, valued at approximately $953,046.40. This represents a 26.52% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.
AngioDynamics Price Performance
NASDAQ ANGO opened at $14.79 on Friday. The business's fifty day moving average is $12.81 and its 200-day moving average is $11.50. The stock has a market capitalization of $611.27 million, a price-to-earnings ratio of -17.00 and a beta of 0.34. AngioDynamics, Inc. has a one year low of $8.36 and a one year high of $15.19.
AngioDynamics (NASDAQ:ANGO - Get Free Report) last posted its quarterly earnings results on Tuesday, July 14th. The medical instruments supplier reported ($0.07) earnings per share for the quarter, beating the consensus estimate of ($0.11) by $0.04. AngioDynamics had a negative net margin of 11.48% and a negative return on equity of 5.73%. The company had revenue of $86.61 million during the quarter, compared to analyst estimates of $80.24 million. AngioDynamics has set its FY 2027 guidance at -0.290--0.240 EPS. Research analysts expect that AngioDynamics, Inc. will post -0.27 EPS for the current fiscal year.
Institutional Trading of AngioDynamics
A number of hedge funds and other institutional investors have recently made changes to their positions in ANGO. Farther Finance Advisors LLC lifted its holdings in AngioDynamics by 146.4% during the 4th quarter. Farther Finance Advisors LLC now owns 2,018 shares of the medical instruments supplier's stock worth $26,000 after purchasing an additional 1,199 shares in the last quarter. Kemnay Advisory Services Inc. purchased a new position in AngioDynamics during the 4th quarter valued at about $27,000. State of Wyoming purchased a new position in AngioDynamics during the 2nd quarter valued at about $31,000. Russell Investments Group Ltd. increased its position in shares of AngioDynamics by 329.5% during the third quarter. Russell Investments Group Ltd. now owns 4,188 shares of the medical instruments supplier's stock valued at $47,000 after buying an additional 3,213 shares during the period. Finally, Tower Research Capital LLC TRC increased its position in shares of AngioDynamics by 359.0% during the second quarter. Tower Research Capital LLC TRC now owns 5,457 shares of the medical instruments supplier's stock valued at $54,000 after buying an additional 4,268 shares during the period. 89.43% of the stock is currently owned by institutional investors.
Analysts Set New Price Targets
A number of research analysts have recently weighed in on ANGO shares. Zacks Research downgraded shares of AngioDynamics from a "hold" rating to a "strong sell" rating in a research report on Thursday, July 16th. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of AngioDynamics in a report on Friday, July 17th. Canaccord Genuity Group upped their price objective on AngioDynamics from $16.00 to $20.00 and gave the company a "buy" rating in a research note on Wednesday, July 15th. Freedom Capital raised AngioDynamics to a "strong-buy" rating in a report on Monday, April 6th. Finally, HC Wainwright raised their target price on AngioDynamics from $16.00 to $19.00 and gave the stock a "buy" rating in a research report on Wednesday, July 15th. One investment analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating and two have assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of "Hold" and a consensus target price of $19.50.
Read Our Latest Research Report on ANGO
AngioDynamics Company Profile
(
Get Free Report)
AngioDynamics, Inc is a medical technology company headquartered in Latham, New York, that develops, manufactures and markets a broad range of minimally invasive medical devices. The company's products focus on three core areas: vascular access, peripheral vascular intervention and interventional oncology. Its solutions are designed to improve procedural outcomes, reduce complications and enhance patient comfort in hospital and outpatient settings.
In the vascular access segment, AngioDynamics offers a portfolio of devices including implanted ports, peripherally inserted central catheters (PICCs), hemodialysis catheters and specialty blood management products.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
